Document is current
Any future updates will be listed below
-
Authors
Iyer, Rishab N. https://orcid.org/0000-0003-4557-4748
Favela, David https://orcid.org/0000-0003-2435-2898
Domokos, Andras https://orcid.org/0000-0002-1722-708X
Zhang, Guoliang
Avanes, Arabo A. https://orcid.org/0000-0001-6211-7966
Carter, Samuel J. https://orcid.org/0000-0002-2276-4373
Basargin, Andrian G. https://orcid.org/0000-0003-3337-9785
Davis, Alexis R.
Tantillo, Dean J. https://orcid.org/0000-0002-2992-8844
Olson, David E. https://orcid.org/0000-0002-4517-0543
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R35GM148182, R01DA056365)
Camille and Henry Dreyfus Foundation
National Science Foundation (XSEDE/ACCESS program)
- License Information
-
More Information
Article History
Received: 27 November 2023
Accepted: 3 December 2024
First Online: 6 February 2025
Competing interests
: D.E.O. is a co-founder of Delix Therapeutics, Inc.; serves as the Chief Innovation Officer and Head of the Scientific Advisory Board; and has sponsored research agreements with Delix Therapeutics. Delix Therapeutics has licensed technology from the University of California, Davis related to analogues of iboga alkaloids. D.E.O., R.N.I. and A.D. have submitted a patent application related to the work described here. The sponsors of this research were not involved in the conceptualization, design, decision to publish or preparation of the manuscript. The remaining authors declare no competing interests.
